A combo dengue rapid diagnostic test can return seven different readable patterns from three lines, and each one points to a different stage of infection. For a desk that already covers malaria and HIV rapid tests, dengue is the case where getting the timing wrong produces the most confusing result — a technically correct negative that still misses an active infection. Understanding what NS1, IgM, and IgG are each measuring is the difference between reading the strip and understanding the patient.
What a Combo Dengue Rapid Test Actually Detects
Most field-deployed dengue RDTs are lateral flow immunoassays that pack three separate readouts into one cassette: an NS1 antigen line, an IgM antibody line, and an IgG antibody line, plus a control line confirming the device ran correctly. A drop of whole blood, serum, or plasma migrates across the strip; if dengue NS1 antigen is present, it binds a capture line and turns visible. Separately, if the patient has already mounted an antibody response, IgM and/or IgG bind their own lines. The three results are read together, not individually — a single line in isolation is a partial answer.
This design exists because dengue diagnosis has a timing problem that malaria and HIV RDTs don’t share to the same degree. NS1 antigen is a viral protein shed during active replication, so it is only reliably present for a narrow window. Antibodies take days to build and then persist — IgM for weeks to months, IgG for life. A test built to catch only one of those signals will miss patients on the wrong side of that window.
Reading the Line Combinations
The same three lines mean something different depending on where the patient is in the illness. This is the pattern most field guidance converges on:
| NS1 | IgM | IgG | Most likely reading |
|---|---|---|---|
| Positive | Negative | Negative | Early primary infection, first few days of illness |
| Positive | Positive | Negative | Acute primary infection, antibody response beginning |
| Positive | Positive | Positive | Possible acute secondary infection (prior dengue exposure) |
| Negative | Positive | Negative | Later primary infection; antigen has cleared, antibodies remain |
| Negative | Negative | Positive | Past infection or long-recovered case |
| Negative | Positive | Positive | Late primary or early secondary infection |
| Negative | Negative | Negative | Does not rule out early infection — retest if illness continues |
The secondary-infection pattern is worth flagging on its own. When a patient has been exposed to dengue before, a new infection can produce a much faster and higher IgG response — sometimes appearing during the acute phase alongside NS1, rather than the slow climb seen in a first infection. That combination is also the pattern epidemiologically associated with more severe disease courses, which is part of why the desk’s separate coverage of the WHO warning signs for severe dengue matters alongside this test-reading guidance, not instead of it.
Why Timing Determines Which Line to Trust
NS1 antigen is generally detectable from around the first day of symptoms through roughly the first week, with the strongest signal typically in the first several days. Antibody testing works on a different clock: IgM typically becomes reliably detectable several days into the illness and can remain positive for weeks to months afterward, while IgG takes longer still to appear and, once present, persists indefinitely as a marker of past exposure.
That offset is the entire logic of the combo format. Early in illness, NS1 is doing the work because antibodies haven’t formed yet. By the time a patient presents later in the first week or into the second, NS1 may have already cleared while IgM has become the more reliable signal. A single-target test read at the wrong moment can report a clean negative on a patient who is, in fact, actively infected — not because the device failed, but because it was only ever built to see one part of the timeline.
What a Negative Result Does — and Doesn’t — Rule Out
A negative result across all three lines is the reading that most often gets over-trusted. It does not reliably exclude early dengue infection, particularly if the sample was collected very early in illness before antigen or antibody levels have risen enough to cross the test’s detection threshold. Programs relying on RDTs as a frontline screen typically build in a retest window of a few days if clinical suspicion remains, rather than treating one negative cassette as the final word. Where serotype confirmation or surveillance-grade certainty is required, that follow-up moves to laboratory-based nucleic acid or serology testing rather than a second field cassette.
This is also where paired sampling earns its place in program protocols: drawing an acute sample and then a convalescent sample roughly a week or more later lets a lab confirm seroconversion directly, which a single rapid test by design cannot do.
Where This Fits in the RDT Landscape
The three-line dengue combo sits alongside the malaria antigen strip and the three-line HIV confirmation protocol this desk has covered elsewhere as a case study in the same underlying principle: a rapid diagnostic test is only as good as the biological window it was validated against. Malaria RDTs are built around a parasite antigen that behaves differently depending on which species is circulating. HIV testing algorithms require sequential tests specifically because a single reactive line isn’t proof on its own. Dengue’s combo format solves a comparable problem by stacking two biological signals — antigen and antibody — onto one strip so that whichever stage a patient walks in during, something is likely to be visible.
For anyone reading results in the field rather than designing the assay, the practical takeaway is the same across all three diseases: know which biological signal the line in front of you is actually measuring, know its detection window, and treat a single negative as informative rather than conclusive when the timeline doesn’t add up.